The Journal of Viral Entry

» Advanced search

CD4⁺ T Cell Decline and Chronic Immune Activation in HIV Disease

Scott F Sieg

An Enhanced-Sensitivity Trofile™ HIV Coreceptor Tropism Assay for Selecting Patients for Therapy with Entry Inhibitors Targeting CCR5: A Review of Analytical and Clinical Studies

Jacqueline D Reeves, Eoin Coakley, Christos J Petropoulos, and Jeannette M Whitcomb

HIV type 1 Entry Correlates with Plasma Membrane Microdomain Lateral Assemblies of Receptors: Implications in HIV/AIDS Treatment

Anu Puri and Robert Blumenthal

Effect of single doses of maraviroc on the QT/QTc interval in healthy subjects

Population pharmacokinetic/pharmacodynamic analysis of CCR5 receptor occupancy by maraviroc in healthy subjects and HIV-positive patients

A population pharmacokinetic meta-analysis of maraviroc in healthy volunteers and asymptomatic HIV-infected subjects

[1] Assessment of the absorption, metabolism, and absolute bioavailability of maraviroc in healthy male subjects
[2] Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers

Potent synergistic anti-human immunodeficiency virus (HIV) effects using combinations of the CCR5 inhibitor aplaviroc with other anti-HIV drugs

Binding modes of CCR5-targetting HIV entry inhibitors: partial and full antagonists

Suppression of dualtropic human immunodeficiency virus type 1 by the CXCR4 antagonist AMD3100 is associated with efficiency of CXCR4 use and baseline virus composition

Major clinical outcomes in antiretroviral therapy (ART)-naïve participants and in those not receiving ART at baseline in the SMART study

Immunogenetic basis of HIV-1 infection, transmission and disease progression

HIV-1 envelope glycoprotein-mediated fusion and pathogenesis: implications for therapy and vaccine development

Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: implications for designing novel anti-HIV fusion inhibitors

In vivo emergence of vircriviroc resistance in a human immunodefiency virus type 1 subtype C-infected subject

Specific enfuvirtide-associated mutational pathways in HIV-1 gp41 are significantly correlated with an increase in CD4⁺ cell count, despite virological failure

Characterisation of the early steps of infection in primary blood monocytes by human immunodeficiency virus type 1

Virological consequences of early events following cell–cell contact between human immunodeficiency virus type 1-infected and uninfected CD4⁺ cells

Chemokine (C–C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naïve individuals

The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen